文献速递哮喘

局部抑制RIPK2减轻屋尘螨诱导的哮喘

Local receptor-interacting protein kinase 2 inhibition mitigates house dust mite-induced asthma.
PubMed 文献 · Eur Respir J · 2024-10-03

本研究在屋尘螨诱导的哮喘小鼠模型及哮喘患者气道上皮细胞中评估局部给予RIPK2抑制剂的预防与治疗作用。预防性给药可减轻野生型小鼠的气道高反应性、嗜酸性粒细胞增多、黏液产生及2型细胞因子,治疗性给药仅降低IL-33;但在人源化NOD1小鼠中治疗性抑制RIPK2可缓解所有哮喘特征。患者上皮培养中抑制剂下调TSLP和趋化因子,提示局部干扰NOD1/RIPK2通路可能成为屋尘螨诱导哮喘的新治疗策略。

要点

  • 局部预防性给予RIPK2抑制剂可减轻野生型小鼠屋尘螨哮喘的气道炎症和黏液产生。
  • 治疗性RIPK2抑制仅在人源化NOD1小鼠中缓解全部哮喘特征,野生型小鼠仅IL-33下降。
  • RIPK2抑制剂可下调哮喘患者气道上皮细胞中屋尘螨诱导的TSLP和趋化因子。

核心结论

  • 局部通过RIPK2抑制干扰NOD1信号通路可能成为屋尘螨诱导哮喘的新治疗途径。

研究设计与样本

  • 在野生型和人源化NOD1小鼠的屋尘螨诱导哮喘模型中,预防性或治疗性鼻内给予RIPK2抑制剂。
  • 评估气道高反应性、支气管肺泡灌洗液组成、细胞因子/趋化因子表达和黏液产生,并检测精准切割肺切片。
  • 在哮喘患者和对照者的气液界面上皮培养中测试该抑制剂。

主要发现

  • 野生型小鼠中,局部预防性给予RIPK2抑制剂降低气道高反应性、嗜酸性粒细胞增多、黏液产生、2型辅助T细胞细胞因子和IL-33。
  • 野生型小鼠中,治疗性给予RIPK2抑制剂未能降低上述参数,但IL-33除外。
  • 人源化NOD1小鼠中,治疗性RIPK2抑制缓解所有哮喘特征。
  • 精准切割肺切片结果强调TSLP和IL-33在NOD1依赖的屋尘螨反应中的早期作用,以及NOD1信号对IL-13效应反应的晚期影响。
  • RIPK2抑制剂下调屋尘螨刺激的哮喘患者上皮培养中的TSLP和趋化因子。

临床怎么用

  • 局部RIPK2抑制可能作为屋尘螨诱导哮喘的潜在治疗策略,尤其对于携带哮喘相关NOD1风险等位基因的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: House dust mite is the most frequent trigger of allergic asthma, with innate and adaptive immune mechanisms playing critical roles in outcomes. We recently identified the nucleotide-binding oligomerisation domain 1 (NOD1)/receptor-interacting serine/threonine protein kinase 2 (RIPK2) signalling pathway as a relevant contributor to murine house dust mite-induced asthma. This study aimed to evaluate the effectiveness of a pharmacological RIPK2 inhibitor administered locally as a preventive and therapeutic approach using a house dust mite-induced asthma model in wild-type and humanised NOD1 mice harbouring an asthma-associated risk allele, and its relevance using air-liquid interface epithelial cultures from asthma patients. METHODS: A RIPK2 inhibitor was administered intranasally either preventively or therapeutically in a murine house dust mite-induced asthma model. Airway hyperresponsiveness, bronchoalveolar lavage composition, cytokine/chemokine expression and mucus production were evaluated, as well as the effect of the inhibitor on precision-cut lung slices. Furthermore, the inhibitor was tested on air-liquid interface epithelial cultures from asthma patients and controls. RESULTS: While local preventive administration of the RIPK2 inhibitor reduced airway hyperresponsiveness, eosinophilia, mucus production, T-helper type 2 cytokines and interleukin 33 (IL-33) in wild-type mice, its therapeutic administration failed to reduce the above parameters, except IL-33. By contrast, therapeutic RIPK2 inhibition mitigated all asthma features in humanised NOD1 mice. Results in precision-cut lung slices emphasised an early role of thymic stromal lymphopoietin and IL-33 in the NOD1-dependent response to house dust mite, and a late effect of NOD1 signalling on IL-13 effector response. RIPK2 inhibitor downregulated thymic stromal lymphopoietin and chemokines in house dust mite-stimulated epithelial cultures from asthma patients. CONCLUSION: These data support that local interference of the NOD1 signalling pathway through RIPK2 inhibition may represent a new therapeutic approach in house dust mite-induced asthma.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Alvarez-Simon D, Ait Yahia S, Audousset C, et al. Local receptor-interacting protein kinase 2 inhibition mitigates house dust mite-induced asthma. Eur Respir J. 2024. PMID: 39117431. doi:10.1183/13993003.02288-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。